Bleomycin Sulfate

Catalog No.S1214 Synonyms: NSC125066

Bleomycin Sulfate Chemical Structure

Molecular Weight(MW): 1512.62

Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

Size Price Stock Quantity  
USD 170 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Bleomycin Sulfate is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
In vitro

UT-SCC-12A and UT-SCC-12B are both more resistant to Bleomycin sulfate with IC50 of 14.2 nM and 13 nM, respectively. [1] Alveolar macrophages incubated with 0.01 μg/mL to 1μg /mL Bleomycin sulfate for 18 hours secretes significantly more fibroblast growth factor than macrophages incubated without Bleomycin sulfate. Macrophages stimulated with Bleomycin sulfate continues to produce significant amounts of fibroblast growth factor even after Bleomycin sulfate is removed and replaced with fresh (Bleomycin sulfate-free) media. Fibroblast growth factor secretion by Bleomycin sulfate-stimulated alveolar macrophages is inhibited by cycloheximide, and the 5-lipoxygenase inhibitors NDGA (nordihydroguaiaretic acid) and BW755c, indicating not only a requirement for protein synthesis but also for metabolites of the 5-lipoxygenase pathway of arachidonic acid metabolism for full expression of activity. [2] Bleomycin sulfate (400 µg/mL) incubation for 24 hours decreases the viability of NTera-2 cells, and increases caspase-3, -8 and -9 activities, Bax and cytoplasmic cytochrome c levels and decreases Bcl-2 levels. [3] In terms of unstable aberrations, the clastogenic effect of Bleomycin sulfate on ADIPO-P2 cells persists for at least 10 days after exposure. Bleomycin sulfate-induced telomere instability in mammalian cells persists for several generations after exposure. Moreover, the appearance of telomere fusions in Bleomycin sulfate-exposed cells 10 days after treatment suggests that Bleomycin sulfate can induce delayed telomere instability. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
F98 NXGzcYRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonPNQKBmzFyMECg{txu M2fTb|I1KGkEoB?= MlvNbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NHTGZW8zPjB6OEexNS=>
POLK WT NX\qSlQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDRdWVyUUN3ME2xNU446oDLwsJihKkyNjgEoN88US=> MWWyOlA{OTRyMB?=
POLK KO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTRwMERihKnDueLCiUGuPVLDqM7:TR?= MViyOlA{OTRyMB?=
POLK CD MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTSTHJKSzVyPUWuOVnjiIoEsfMAjVEvODEEoN88US=> M1fzWFI3ODNzNECw
RLE/Abca3 M{jmdGZ2dmO2aX;uJGF{e2G7 NYTvZXlXOC52wrFOwG0> NULxSpVYOTR2wrDo M2\0UYlv\HWlZYOgZUBud3KyaH;sc4dq[2GuIHPoZY5o\SCocn;tJIVxcXSqZXzpZYwudGmtZTDtc5JxcG:ub3f5JJRwKGFid3nk[Uwhe3C{ZXHkMY92fCCvb4LwbI9td2e7wrC= M1fy[|I2PzZyNUO4
PMCs M3HH[WZ2dmO2aX;uJGF{e2G7 MlX3NE4y6oDVMtMg{txoN22u NVjK[GdWOjUEoHi= Mlm4Z4F2e2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKHC{b4TlbY4hdGW4ZXygc4Yh[2:ubHHn[Y4uUcLi NEPucGkzPTV7NU[0Ni=>
PMCs M{TvPGZ2dmO2aX;uJGF{e2G7 NUjqR4VxOC5{wrFOwIcwdWx? NIHR[40zPOLCk{eyxsBp NXPxTJBOcW6mdXPld{BqdmO{ZXHz[ZMhcW5idnnt[Y51cW5iYX7kJO6yNVOPQTDwdo91\Wmw NXSxOHMxOjV3OUW2OFI>
PMCs NHrkbVFHfW6ldHnvckBCe3OjeR?= NEfpSWUxNjMEoN88[{9udA>? NEO5OIs4OiCq MofrbY5lfWOnczDk[YNz\WG|ZYOgbY4h[3m2b3vldoF1cW5vODDhcoQhTS2lYXTo[ZJqdiCycn;0[Ylv NF6zTHUzPTV7NU[0Ni=>
PMCs NYTtOmNZTnWwY4Tpc44hSXO|YYm= NVzDfFR7OC5{wrFOwIcwdWx? NYjBNJBqOTJxMkSvOFghcA>? M1;2WYlv[3KnYYPld{Bk\WyuIH3p[5JifGmxbh?= NUTzeHdTOjV3OUW2OFI>
IMR-32 M13zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XyflcvPeLKkkGyNEDDvWdxbXy= M2DDdFEz6ojUNEigbC=> NEDlPYxKSzVyPU[wJOK2\y:vbDDheEB1cGViZX7kJI9nKDJ2IHjyd{Bw\iCrbnP1ZoF1cW:w M331V|I2PTN4M{S1
HT1080 M37ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DuelEh|ryP NGTjdIUzPCCqwrC= NGOyRYJt\WGmczD0c{BiKEd{L12g[IVt[Xl? MnixNlU2OTh7NkG=
HT1080 MnT2SpVv[3Srb36gRZN{[Xl? NHP1bnUyKM7:TR?= NWrGcY5sOjRiaNMg NIHtWmVqdmS3Y3XzJIEheG:2ZX70JIdtd2KjbDDEUmEh\GGvYXflJJJme3CxboPl Mn7xNlU2OTh7NkG=
HDFn MnrUR5l1d3SxeHnjbZR6KEG|c3H5 MYS3NkBp M{XGeWlEPTB;OT6zNUXDqA>? MojkNlUzPzZ5OUK=
THP-1 MXLDfZRwfG:6aXPpeJkhSXO|YYm= MX63NkBp NGPodolKSzVyPUSuO|cm MnfONlUzPzZ5OUK=
HT-29 NXz5fWpjS3m2b4TvfIlkcXS7IFHzd4F6 MnuzO|IhcA>? MVPJR|UxRTFzLkS5KS=> NVfSbId7OjV{N{[3PVI>
HCT116  Mo\lR5l1d3SxeHnjbZR6KEG|c3H5 M3:4RVczKGh? MoLGTWM2OD1zMT6zOEU> NIHke40zPTJ5Nke5Ni=>
A431 MnLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjMW3VXPTBvMkCwJGlW Ml7BOFjjiImq NGjMVGhqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1vBO|I2OTBzMkm5
T24 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHNdGs2OC1{MECgTXU> M1K0OVQ56oDLaB?= MkjTbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NY\HeVFTOjVzMEGyPVk>
AY-27  MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHxW2g{PTBvMkCwJGlW M1LDN|Q56oDLaB?= NWL4W|VHcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NIPYZXkzPTFyMUK5PS=>
A549 M1Tr[mZ2dmO2aX;uJGF{e2G7 NELR[5QyKML3Zz;tUOKh MWKwMVQ5KGh? NUHPdY1zcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? NHnjSoEzPDl4M{[zOS=>
MLE12 NFn3cXZHfW6ldHnvckBCe3OjeR?= NFnKfGMyKML3Zz;tUOKh MmC0NE01QCCq NWnCUZFDcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nyqCRUF9CpI1TVkF? MYCyOFk3OzZ|NR?=
Jurkat NVvpdFZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTET5o6OjEkgJpOwI0> NWS1W5VtOjUkgJnoxsA> Mlj3ZZJz\XO2czD0bIUh[2WubDDjfYNt\SCjdDD0bIUhTzJicHjhd4U> M2PlRVI1QTF4OEmz
HeLa  NWLJTFJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLXTWM2OD1zMD6yxsDPxE1? NGjvPGwzPDd|MkO5Oy=>
C18-4 Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzoNE0yODBizszN NFLBcGpqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MkDTNlQ2PzF7OEK=
BMG-1  NVfI[FFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjZVpk1OC96MNMg{txoN21? MkjyN:KhcA>? MlvEbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NIDp[WozOzlyNkeyOi=>
A459 MkfBRZBweHSxc3nzJGF{e2G7 MmXYNVAhdVV? NHn3OFY1QCCq NYn3[WwzcW6mdXPld{BieG:ydH;zbZM> NVvJW2x3OjN7MEK3OlY>
MOCK MnXoRZBweHSxc3nzJGF{e2G7 MnSwNVAhdVV? MVu0PEBp M{fibYlv\HWlZYOgZZBweHSxc3nz M4jXcFI{QTB{N{[2
MMP1 MoDjRZBweHSxc3nzJGF{e2G7 NX;pSXlYOTBibWW= M2PZe|Q5KGh? NUPIbGxJcW6mdXPld{BieG:ydH;zbZM> MoiwNlM6ODJ5Nk[=
A549 NFXhc3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3noO|IxOCEQvF2= MWSyOEBpyqB? MkDT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NXTMXYVLOjN6MEW3PVM>
HCT-116 MXzBdI9xfG:|aYOgRZN{[Xl? M{\XOVMwPy53L{G1JO69\y:vbB?= NYDmTGVnPDhiaB?= MVzy[YR2[2W|IITo[UBt\X[nbDDv[kBDVEhiYYSgbIlocCClb37j[Y51emG2aX;u NVW2OoNROjN5MEi2Olg>
HeLa MVzBdI9xfG:|aYOgRZN{[Xl? NIrvUY8{NzdwNT:xOUDPxGdxbXy= MmHiOFghcA>? Mn3jdoVlfWOnczD0bIUhdGW4ZXygc4YhSkyKIHH0JIhq\2hiY3;uZ4VvfHKjdHnvci=> NYn3enZkOjN5MEi2Olg>
HCT116 NWLufGhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET1eVUxNTFyMDFOwIcwdWx? MYC0PEBp NIrxUHpqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NELXS48zOzVzOEKwNS=>
NCM460 NYXzeIptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHBUIpEOC1zMECg{txoN22u NHH2enc1QCCq MlT1bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> M3zzb|I{PTF6MkCx
NT2  NYHLSXN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfvOXMzPCCqwrC= NV3M[GJLVER3ME20NFDjiIoEtXevcYw> MnGxNlM{QDZ2MkC=
NT2  MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnsOFghcA>? MVnMSFUxRTFyMDFCuYcwdWx? MX2yN|M5PjR{MB?=
NT2  Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTiO|IhcA>? MmXQUGQ2OD1{MPMAjeK2\y:vbB?= MVSyN|M5PjR{MB?=
NT2  M2PmcGFxd3C2b4Ppd{BCe3OjeR?= NXTJVXR2PDBy4pEJxtVoN22u NF3NTG0zPCCqwrC= M17HPYlv\HWlZYOgd4lodmmoaXPhcpQhcW6lcnXhd4V{KGmwIHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? M1LuN|I{Ozh4NEKw
NTera-2 MmfISpVv[3Srb36gRZN{[Xl? Mon4NVIxKM7:Zz;tcC=> M1SxcVczKGh? MYLzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyB6LXnzc5Bzd3O2YX7lJIxmfmWucx?= NFPhRXUzOjh{NUO1OS=>
NCCIT NWPITXNLTnWwY4Tpc44hSXO|YYm= MWixNlAh|rypL33s Mm\zO|IhcA>? NFfv[Yl{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczC4MYl{d3C{b4P0ZY5mKGyndnXsdy=> NUjOZ|Z1OjJ6MkWzOVU>
NTera-2 NYjaWoRxTnWwY4Tpc44hSXO|YYm= NEW3XXEyOjBizsznM41t M37sZlczKGh? MnPEd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiVFLBVnMhdGW4ZXzz NFzPR2UzOjh{NUO1OS=>
NCCIT Mo\zSpVv[3Srb36gRZN{[Xl? NGrUOpQyOjBizsznM41t M{DwNlczKGh? NVL5NFU6e2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgWGJCWlNibHX2[Yx{ NF\XSIYzOjh{NUO1OS=>
NCCIT MVHGeY5kfGmxbjDBd5NigQ>? NGjTeJMyOjBizsznM41t NX7DS4VsPzJiaB?= MYXzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCJU1igcIV3\Wy| MVKyNlgzPTN3NR?=
NTera-2 M4DJO2Z2dmO2aX;uJGF{e2G7 M1q4flEzOCEQvHevcYw> MYe3NkBp MoHPd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> M1vx[FIzQDJ3M{W1
NCCIT MYnGeY5kfGmxbjDBd5NigQ>? NV3YUFN7OTJyIN88[{9udA>? MUm3NkBp Mmizd4lodmmoaXPhcpRtgSCrbnPy[YF{\XNiUILveIVqdiClYYLic456dCCuZY\lcJM> MkXoNlI5OjV|NUW=
NTera-2 MlnjSpVv[3Srb36gRZN{[Xl? NWLhOVYzOTJyIN88[{9udA>? NFHX[4M4OiCq NFi4Z3B{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczDMVG8hdGW4ZXzz M1zyV|IzQDJ3M{W1
NCCIT MnrCSpVv[3Srb36gRZN{[Xl? M1\MPVEzOCEQvHevcYw> MYG3NkBp M{nB[JNq\26rZnnjZY51dHliaX7jdoVie2W|IFzQU{Bt\X[nbIO= NGn4cHgzOjh{NUO1OS=>
MDA-MB-468 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGw5qCUOjBywrFOwIcwdUx? NInySY4zPCCq NWPIepZ1cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MUmyNlgyQTF7Nh?=
231-H2N NEflSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[w5qCUOjBywrFOwIcwdUx? MXGyOEBp M3\XV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NWGzfWZMOjJ6MUmxPVY>
A549  NVrq[pdqTnWwY4Tpc44hSXO|YYm= NXK4eHd7OjByL{SwNEDPxE1? MYry[ZN2dHS|IHnuJIEh\G:|ZT3y[ZNxd26|aY\lJIlv[3KnYYPlJIlvKFKRUx?= M1nPVFIzPzd|Nkm3
A549  MYrGeY5kfGmxbjDBd5NigQ>? NX3QPXRVOC12MECg{txO NWTjWpFvOi12ODDo MXnjZZV{\XNibX;y[UBufESQQTD0bIFvKG6GTlGg[IFu[Wen MYeyNlc4OzZ7Nx?=
A549  MYTGeY5kfGmxbjDBd5NigQ>? NIT6[24yODBizszNxsA> NVnGcmFFOOLCk{S4JIg> M4nwSoNifXOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> MUGyNlc4OzZ7Nx?=
A549  NWfFfHl[TnWwY4Tpc44hSXO|YYm= NIXFc4kyODBizszNxsA> NWr3Zm1vOOLCk{S4JIg> NFG4e4xk[XW|ZYOgVGtFOSClbHXheoFo\Q>? MnfNNlI4PzN4OUe=
A549  NHHxXWtHfW6ldHnvckBCe3OjeR?= MYWxNFAh|ryPwrC= MkTrNQKBmzR6IHi= Mn;OZ4F2e2W|IH3peI9kcG:wZILpZYwhdG:lYXzpfoF1cW:wIH;mJGJigA>? M4fxTFIzPzd|Nkm3
A549  MkDLSpVv[3Srb36gRZN{[Xl? Ml6zNVAxKM7:TdMg NG[xe3cx6oDVNEigbC=> NILO[XZl\WO{ZXHz[ZMhVU2SIHHu[EBCXFBibHX2[Yx{ MVGyNlc4OzZ7Nx?=
MCF-7/Her-18  M3HCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj4bZExNjR{LUG3NFAh|rypL33M MWKyOEBp NI\GV4FqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M3G1RlIzPjJzNEC0
MCF-7 MonVVGRVN1CFSTDUdoVifG2nboS= MVGwMlI2KM7:Zz;tcE4> Mlj6NU01KGh? NV;vRYdVe2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? MX[yNlU6OTJ6NB?=
MDA-MB-231 M4r5VnBFXC:SQ1mgWJJm[XSvZX70 NFzsfGExNjJ3IN88[{9udC5? M3yxO|EuPCCq NXvoZ5J6e2ixd4Ogd4lodmmoaXPhcpQhMFEEoEygNE4xPSliY4n0c5RwgGmlIHXm[oVkfA>? M{[zVVIzPTlzMki0
MDA-MB-235  MWfQSHQwWEOLIGTy[YF1dWWwdB?= NXq0bYduOC5{NTFOwIcwdWxw NHz1UGgyNTRiaB?= MmXmd4hwf3Nic3nncolncWOjboSgLHDDqDxiMD6wOUkh[3m2b4TvfIlkKGWoZnXjeC=> MlfYNlI2QTF{OES=
MCF-7 MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYX3VZRuOC1{IN88[{9udC5? MXeyOE81QCCq M2fVZ2VEPTB;MT6yJO69\y:vTB?= M1r4XVIzPTlzMki0
NCCIT  MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrVNlDjiJNzNEFCpO69\y:vbB?= NEDp[ok4OiCq MYXMSFUxRTF{MNMg{txoN22uwrC= M1zEV|IzPTZ{MU[w
NCCIT  MojzSpVv[3Srb36gRZN{[Xl? MVi3NkBp M{TSNpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzDhZ5Rqfmm2edMg M1rKS|IzPTZ{MU[w
NCCIT  MmLLSpVv[3Srb36gRZN{[Xl? MYK3NkBp MVLzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyClYYPwZZNmNThiYXP0bZZqfHoEoB?= M1TRe|IzPTZ{MU[w
NCCIT  MlKxSpVv[3Srb36gRZN{[Xl? NYn6c5BUPzJiaB?= M1\J[JNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvOTDhZ5Rqfmm2edMg M2f0dVIzPTZ{MU[w
NCCIT  NFrGcmxHfW6ldHnvckBCe3OjeR?= MlTkO|IhcA>? MUnzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyCEQWigcIV3\Wx? NWfwOZN3OjJ3NkKxOlA>
NCCIT  NGfuXGpHfW6ldHnvckBCe3OjeR?= MXi3NkBp M{jVeJNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBD[2xvMjDjc451\W62 MkTKNlI2PjJzNkC=
NCCIT  MWrGeY5kfGmxbjDBd5NigQ>? NIr3NXk4OiCq M32wfpNq\26rZnnjZY51dHliZHXjdoVie2W|IITo[UBEgXRvYzDs[ZZmdA>? NX;ISJdDOjJ3NkKxOlA>
HeLa NYDweIk1TnWwY4Tpc44hSXO|YYm= NHOzOXA{OC95MDFOwIcwdWx? MWmyOOKhcA>? M{K3dolv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqHB3M,-8kGFVVSyyMkJCpIFv\MLiR1HESFQ2 MlLyNlI1QDd7M{e=
MCF-7  M3HFR2Z2dmO2aX;uJGF{e2G7 NEi5NYs{OC95MDFOwIcwdWx? MX:yOOKhcA>? MX\pcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBxPTQxvJzBWG0teDJzwrDhcoTDqEeDRFS0OS=> NXXuc29[OjJ2OEe5N|c>
HeLa MUPDfZRwfG:6aXPpeJkhSXO|YYm= M3zFTVMxNzdyIN88[{9udA>? MXyyOOKhcA>? MXnpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? M1PNN|IzPDh5OUO3
MCF-7  NXzoXHl[S3m2b4TvfIlkcXS7IFHzd4F6 M1;rZVMxNzdyIN88[{9udA>? NVXE[IJYOjUEoHi= MWfpcoR2[2W|IHjp[4htgSC|aXfubYZq[2GwdDDs[ZZmdHNib3[g[pJi\22nboTl[EBFVkFicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21? M2fQNlIzPDh5OUO3
NT2 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xNFAuPjBywrFOwIcwdWx? MV:yOEBp M4HvbmlEPTB;NECwJOK2\y:vbB?= NFTDcY0zOjR4OUm1Ni=>
NT2 M{npTWZ2dmO2aX;uJGF{e2G7 NEixfpE1ODEEoN88[{9udA>? NEPMbnAzPCCq M2[5WpNq\26rZnnjZY51dHliaX7jdoVie2W|IHPhd5Bie2VvMzy4MFkh[WO2aY\peJnDqA>? NYnHPGw5OjJ2Nkm5OVI>
NT2 M{jNVGZ2dmO2aX;uJGF{e2G7 NIrjcmc1ODEEoN88[{9udA>? M1XuW|I1KGh? NVrUXGxFe2mpbnnmbYNidnSueTDpcoNz\WG|ZYOgRmFZKGyndnXs MlTvNlI1Pjl7NUK=
NT2 MnfaSpVv[3Srb36gRZN{[Xl? MljoOFAxyqEQvHevcYw> M2K3[lI1KGh? NXTGXXBle2mpbnnmbYNidnSueTDk[YNz\WG|ZYOgRoNtNTJibHX2[Yw> NUK5OYVKOjJ2Nkm5OVI>
CHO M{ntN2Z2dmO2aX;uJGF{e2G7 M3[0elIvPcLizsznM41t NH;NcoIyQCCqL{[g[C=> NILo[3pqdmS3Y3XzxsBx\XK|aYP0[Y5k\SCxZjDjbJJwdW:|b33lJIRidWGpZR?= NX3FWI1TOjJ{M{CxPVU>
Jurkat MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO2bXF7OC1zMEFCpO69\y:vbB?= NHT0UpozPCCq NGDncmFienKnc4TzJJRp\SClZXzsJIN6[2ynIHH0JJRp\SCJMjDwbIF{\Q>? NHf0fVYzOjJ{M{OzNi=>
Jurkat Ml\0SpVv[3Srb36gRZN{[Xl? NYXOZodjOzEEoN88[{9udA>? NH22UHozPCCq Ml36bY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCleXPsbY5{KER|LDDBJIFv\CCEMR?= NXnvT21POjJ{MkOzN|I>
Jurkat MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HrdlAuOTBywrFOwIcwdWx? MXmyOEBp M3LMSolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkB4cXSqIHHuJGlEPTBidnHseYUhd2ZiMUCw{txoN22O NWLQT5BZOjJ{MkOzN|I>
Jurkat NIT4WJhHfW6ldHnvckBCe3OjeR?= MWSzNOKh|rypL33s M3S2XVI1KGh? NEHqSoxqdmO{ZXHz[ZMhfGinIHXm[oVkfCCxZjDwfYNvcWSrb37lJI9vKHCqb4PwbI9zgWyjdHnvckBt\X[nbIOgc4YhcGm|dH;u[UBJOkFwWB?= MmTiNlIzOjN|M{K=
U2OS EGFPnls MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DSWlAuOsLizsznM41t M3;zWFI1KGh? MV7pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NEi4eG8zOThzMUCwOy=>
U2OS KuEnls MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlm3NE0zyqEQvHevcYw> M3;1VVI1KGh? MUfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 M3;CbVIyQDFzMEC3
MCF-7 NIn3RnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnHe|ExNTRyMDFOwG0> MVS3NkBp MVnMR|UxRTF3MT64xsDPxE1? MkP6NlE4ODN{OUG=
MCF-7/Adr  MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfvcGpnOC12MECg{txO M3fLOVczKGh? NEOwTJlNSzVyPUW4MlXDqM7:TdMg NUnWZ5Z{OjF5MEOyPVE>
WI-38 M1\acmZ2dmO2aX;uJGF{e2G7 M37QN|AwPDBxOEFihKnPxGdxbX|CpC=> MV2zJIg> MX\pcoR2[2W|IHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRiaX7jdoVie2ViaX6geIhmKE2QIH\y[ZF2\W6ledMg MoToNlE2QTl4MUK=
hBMSC MULGeY5kfGmxbjDBd5NigQ>? M4O1cVAwPDBxOEFihKnPxGdxbX|CpC=> MUezJIg> MmDLbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> NWfScW1oOjF3OUm2NVI>
NCI-H23 NHHkRYxHfW6ldHnvckBCe3OjeR?= NHLSS2MxNzRyL{iw5qCK|rypL33sxsA> NHnNTmI{KGh? NHO0S2JqdmS3Y3XzJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5kemWjc3WgbY4hfGinIF3OJIZz\XG3ZX7jfeKh NUPCdXdTOjF3OUm2NVI>
A-549 NXOzOIJsTnWwY4Tpc44hSXO|YYm= M4TMflAwPDBxOEFihKnPxGdxbX|CpC=> NI\sWW8{KGh? M{fkdolv\HWlZYOgZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcoNz\WG|ZTDpckB1cGViTV6g[pJmeXWnbnP5xsA> MnXLNlE2QTl4MUK=
PBL  MXPGeY5kfGmxbjDBd5NigQ>? M161WVAwPDBxOEFihKnPxGdxbX|CpC=> MkGwN{Bp MlXMbY5lfWOnczDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJJRp\SCPTjDmdoVyfWWwY4pCpC=> M{XZd|IyPTl7NkGy
pol β −/− NEDxZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\6S20xNjJ3LUKwNOKh|rypL33s Mo\KNlTDqGh? NV;1R4k4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li M{LnZVIyOjVzOUS0
pol β +/+ NHHLPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq0[lUxOC5{NT2yNFDDqM7:Zz;tcC=> MVWyOOKhcA>? NVWxfXVV\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJdqfGhiaX7jdoVie2mwZzDjc45k\W62cnH0bY9ve8Li NWf0[pF6OjF{NUG5OFQ>
pol β −/− NX3RcmV2TnWwY4Tpc44hSXO|YYm= NHjBeHoxNTJwNTFOwIcwdWx? MWmyJIg> M1rCSoNifXOnczDEUmEh\GGvYXfl MVWyNVI2OTl2NB?=
pol β +/+ NWnEfGdZTnWwY4Tpc44hSXO|YYm= NGHjN5kxNTJwNTFOwIcwdWx? MWWyJIg> NHzJdm5k[XW|ZYOgSG5CKGSjbXHn[S=> MoX0NlEzPTF7NES=
pol β −/− M2HFTmZ2dmO2aX;uJGF{e2G7 MojjNE02KM7:Zz;tcC=> NFzqOm41QCCq NUjSRmRj[2G3c3XzJI1q[3KxboXjcIV2eyCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 MY[yNVI2OTl2NB?=
pol β +/+ M2XtZWZ2dmO2aX;uJGF{e2G7 NGXDUoExNTVizsznM41t NHr4U401QCCq MUPjZZV{\XNibXnjdo9vfWOuZYXzJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MWqyNVI2OTl2NB?=
TK6  M1jFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKyOU0yPTBizsznM41t M1\vS|k3KGh? MYfpcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 MlfxNlExQDF2OEe=
TK6  sLUC+Apn1 M4jYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHUNlUuOTVyIN88[{9udA>? M2rlb|k3KGh? MlnXbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NGPqXXAzOTB6MUS4Oy=>
TK6 sAPE1+Apn1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\lSZVSOjVvMUWwJO69\y:vbB?= NVi3OJFOQTZiaB?= NFfiXYZ{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= M{HpOFIyODhzNEi3
HCT116 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIntbGszPS1zNUCg{txoN22u NYLzbXJ2QTZiaB?= M1r0S4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NXPRTJpZOjFyOEG0PFc>
HCT116 sLUC+Apn1 NFfKSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKyOU0yPTBizsznM41t M1TNblk3KGh? M{PMXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NUjneoJ5OjFyOEG0PFc>
HCT116 sAPE1+Apn1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYj2elNEOjVvMUWwJO69\y:vbB?= NVzaWXFRQTZiaB?= NEXWUJN{cWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwh\3Kxd4ToJIRwe2ViZHXw[Y5l\W62bIm= MkX1NlExQDF2OEe=

... Click to View More Cell Line Experimental Data

In vivo Day 7 post-Bleomycin sulfate, CD45+ cells in BALf in NOX-/- is 1.7-fold > WT, 57% of which are Mf that decreases by 67% in WT and 83% in NOX-/- by Day 21. [5]

Protocol

Cell Research:

[4]

+ Expand
  • Cell lines: ADIPO-P2 cells
  • Concentrations: 2.5 μg/mL
  • Incubation Time: 30 minutes
  • Method:

    ADIPO-P2 cells are grown in D-MEM high glucose medium supplemented with 20% fetal calf serum, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 °C and 5% CO2 atmosphere. Cells are cultured as monolayer in TC25 Corning flasks containing 1.5 × 105 cells/mL. For each experiment, two flasks are set up, one for the control and one for the treated culture. During the log phase of growth ADIPO-P2 cells are treated with a 30 minutes pulse of 2.5 μg/mL of Bleomycin sulfate. Control cultures are set up in parallel but not exposed to Bleomycin sulfate. Time of exposure and concentration of Bleomycin sulfate are chosen according to previous studies carried out in our laboratory with mammalian cells exposed to Bleomycin sulfate. At the end of the pulse treatment with Bleomycin sulfate, the cells are washed twice with Hank's balanced salt solution and kept in culture with fresh culture medium until harvesting. Cells are continuously maintained in culture during 5 passages or subcultures after treatment. Subcultivation is carried out whenever the cultures became confluent (approximately 4 × 105 cells/mL of culture medium). To estimate cell growth, at the time of subcultivation cells are collected by trypsinization, an aliquot of about 200 μL stained with 0.4% trypan blue, and the number of viable cells is determined. Cells are then suspended in fresh culture medium and dispensed into new culture flasks containing 1 × 105 cells/mL to continue growing. The rest of the cells is discarded or dispensed in another flask for cytogenetic analysis, which is performed at 18 hours and 10 days after the end of treatments. To analyze chromosomal aberrations, colchicine (0.1 μg/mL) is added to cell cultures during the last 3 hours of culture. Chromosome preparations are made following standard procedures. After harvesting, cells are hypotonically shocked, fixed in methanol:acetic acid (3:1), spread onto glass slides and processed for PNA-FISH. Two independent experiments are carried out.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: CD-1 mice
  • Formulation: Saline
  • Dosages: 5 mg/kg, 2 ml/kg
  • Administration: Administered via i.t.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL warmed (66.11 mM)
Water 100 mg/mL (66.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 1512.62
Formula

C55H85N17O25S4

CAS No. 9041-93-4
Storage powder
in solvent
Synonyms NSC125066

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02166463 Recruiting Classical Hodgkin Lymphoma|Stage IIB Hodgkin Lymphoma|Stage IIIB Hodgkin Lymphoma|Stage IVA Hodgkin Lymphoma|Stage IVB Hodgkin Lymphoma National Cancer Institute (NCI) March 2015 Phase 3
NCT02582697 Recruiting Germ Cell Tumor University of Sydney|Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Cambridge University Hospitals NHS Foundation Trust|Cancer Trials Ireland|Childrens Oncology Group|Dana-Farber Cancer Institute|University of Southern California February 2014 Phase 3
NCT01390584 Recruiting Lymphoma Eastern Cooperative Oncology Group|National Cancer Institute (NCI) April 2012 Phase 2
NCT01132807 Active, not recruiting Lymphoma Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) May 2010 Phase 2
NCT01042522 Recruiting Ovarian Granulosa Cell Tumor|Ovarian Gynandroblastoma|Ovarian Sertoli-Leydig Cell Tumor|Ovarian Sex Cord Tumor With Annular Tubules|Ovarian Sex Cord-Stromal Tumor|Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types|Ovarian Steroid Cell Tumor Gynecologic Oncology Group|National Cancer Institute (NCI) February 2010 Phase 2
NCT01026220 Active, not recruiting Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma|Stage III Childhood Hodgkin Lymphoma|Stage IV Childhood Hodgkin Lymphoma Childrens Oncology Group|National Cancer Institute (NCI) December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what is the ratio between bleomycin A2 and bleomycin B2 in your product?

  • Answer:

    The content of Bleomycin A2 and Bleomycin B2 is 62% and 29% respectively.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Bleomycin Sulfate | Bleomycin Sulfate ic50 | Bleomycin Sulfate price | Bleomycin Sulfate cost | Bleomycin Sulfate solubility dmso | Bleomycin Sulfate purchase | Bleomycin Sulfate manufacturer | Bleomycin Sulfate research buy | Bleomycin Sulfate order | Bleomycin Sulfate mouse | Bleomycin Sulfate chemical structure | Bleomycin Sulfate mw | Bleomycin Sulfate molecular weight | Bleomycin Sulfate datasheet | Bleomycin Sulfate supplier | Bleomycin Sulfate in vitro | Bleomycin Sulfate cell line | Bleomycin Sulfate concentration | Bleomycin Sulfate nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID